ZURICH, Switzerland, December 2024 – Venture Valuation/Biotechgate (the “Company”) a leader in life science valuation and data solutions, is pleased to announce its participation in JPM Week 2025, taking place in San Francisco this January. The week, centered around the J.P. Morgan Healthcare Conference, is one of the most significant gatherings in the life sciences calendar.
During the week, the Company will attend the following events:
- Sachs 8th Annual Neuroscience Innovation Forum – January 12, 2025
- Biotech Showcase – January 13-15, 2025
- RESI (Redefining Early Stage Investments) JPM 2025 – January 14, 2025
Highlighting the Company’s presence at JPM Week, CEO Dr. Patrik Frei will deliver a presentation at the RESI event, focusing on life science company valuation strategies and best practices.
“JPM Week is the most important event in the life sciences calendar, and we are excited to participate as well as connect and re-connect with fellow life science professionals,” said Dr. Frei. “Our presence at these events underscores our commitment to supporting the life sciences ecosystem with accurate, data-driven insights and valuations that drive informed decision-making.”
The Company welcomes the opportunity to connect with attendees during these events and provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can schedule a one-on-one meeting with the Company’s delegates using the conference portals. Alternatively, they can get in touch at contact@venturevaluation.com.
About Venture Valuation:
Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology (Biotech), medical technology (MedTech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.
About Biotechgate:
Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 60,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 35,000 licensing deals and a clinical trials database containing over 900,000 records from registries around the world.